Substituted Nucleoside Analogues Enhancing PRMT5 Inhibitor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a strong need for novel PRMT5 inhibitors to address the challenge of cancer treatment, particularly for mantle cell lymphoma, as existing options are limited and current inhibitors are not selective enough.
Innovation Solution
Development of novel substituted nucleoside analogues that inhibit PRMT5 activity, which can be used in pharmaceutical compositions to treat various diseases including cancer, by targeting specific biochemical pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PRMT5 inhibitors are used, then PRMT5 activity is inhibited, but selectivity is insufficient leading to off-target effects
Solution Approach 1:
The patent introduces specific substituent patterns at defined positions of the nucleoside analogue structure to enhance selectivity for PRMT5 over other methyltransferases. By optimizing local chemical properties (hydrophobicity, hydrogen bonding capacity, steric bulk) at specific regions of the molecule, the compounds achieve preferential binding to PRMT5's active site while minimizing interactions with off-target enzymes.
Solution Approach 2:
The patent systematically varies key molecular parameters including substituent type (halogen, alkyl, aryl), substituent position, and linker flexibility to tune binding affinity and selectivity. By changing these chemical parameters across a series of analogues, the invention identifies optimal configurations that maximize PRMT5 inhibition while reducing off-target effects.
2Reliability
If novel substituted nucleoside analogues are developed, then selectivity and efficacy are improved, but development complexity and time increase
Solution Approach 1:
The patent divides the nucleoside analogue into distinct functional modules: a core nucleoside structure, variable substituent groups at specific positions, and linker regions. This segmentation allows independent optimization of each module's properties (metabolic stability, binding affinity, cellular uptake) and facilitates systematic structure-activity relationship studies to streamline development.
Solution Approach 2:
The patent designs a versatile nucleoside analogue scaffold that can accommodate multiple substituent types and configurations while maintaining core PRMT5 inhibition activity. This universal platform enables generation of multiple derivatives from a single core structure, reducing overall development complexity by reusing validated structural elements across different candidate compounds.
Data Source
AI summary
The present invention relates novel substituted nucleoside analogues of Formula (I)wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.